Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma
Abstract Current treatment strategy for kidney renal clear cell carcinoma (KIRC) is limited. Tumor-associated antigens, especially neoantigen-based personalized mRNA vaccines represent new strategies and manifest clinical benefits in solid tumors, but only a small proportion of patients could benefi...
Main Authors: | Hang Xu, Xiaonan Zheng, Shiyu Zhang, Xianyanling Yi, Tianyi Zhang, Qiang Wei, Hong Li, Jianzhong Ai |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-12-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12943-021-01465-w |
Similar Items
-
Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine
by: Xiaonan Zheng, et al.
Published: (2021-12-01) -
Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
by: Shuai Ma, et al.
Published: (2021-09-01) -
Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine
by: Hua Zhong, et al.
Published: (2021-08-01) -
LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically ‘Cold’ KIRC Tumours
by: Shichao Zhang, et al.
Published: (2023-02-01) -
Dissecting tumor antigens and immune subtypes for mRNA vaccine development in breast cancer
by: Lang Li, et al.
Published: (2023-09-01)